{"id":54990,"date":"2023-03-20T14:06:39","date_gmt":"2023-03-20T13:06:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/"},"modified":"2023-03-20T14:06:39","modified_gmt":"2023-03-20T13:06:39","slug":"phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/","title":{"rendered":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting"},"content":{"rendered":"<div>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502\/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/5\/Nimbus_logo_RGB_NoTM_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg\"><\/a><\/p>\n<p>\nThe results were presented as part of the Late-Breaking Research session by April Armstrong, M.D., MPH, clinical investigator in the Phase 2b study and Associate Dean and Professor of Dermatology at the University of Southern California.\n<\/p>\n<p>\nFrom Takeda\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Fnewsroom%2Fnewsreleases%2F2023%2Ftakeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279&amp;esheet=53363887&amp;newsitemid=20230317005414&amp;lan=en-US&amp;anchor=press+release&amp;index=1&amp;md5=27b7de5e55ab16ce9e7505cc1893eed2\" rel=\"nofollow noopener\" shape=\"rect\">press release<\/a> dated March 18th:\n<\/p>\n<p>\n<i>In the Phase 2b study, 259 patients were randomized (1:1:1:1:1 ratio) to receive one of four doses of TAK-279 once-daily, or placebo for 12 weeks.<sup> <\/sup>Results showed:<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<i>A significantly greater proportion of TAK-279 patients achieved PASI 75 (44%, 68%, 67%; 5mg, 15mg, 30mg, respectively) versus placebo (6%; p&lt;0.001), meeting the study\u2019s primary endpoint.<\/i>\n<\/li>\n<li>\n<i>A significantly greater proportion of TAK-279 patients achieved PASI 90 (21%, 45%, 46%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p&lt;0.001), and PASI 100 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p&lt;0.001 at 30mg).<\/i>\n<\/li>\n<li>\n<i>A significantly greater proportion of TAK-279 patients achieved Physician Global Assessment (PGA) scores of 0\/1 (27%, 49%, 52%; 5mg, 15mg, 30mg, respectively) or 0 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (4% [p\u22640.001] and 0% [p&lt;0.001 at 30mg], respectively) at 12 weeks. A PGA score of 1 indicates almost clear skin and 0 indicates totally clear skin.<\/i>\n<\/li>\n<li>\n<i>There were no statistically significant differences in PASI or PGA response rates seen in the TAK-279 2mg arm (18%, 2%, 10%, 2%; PASI 75, PASI 100, PGA 0\/1, PGA 0, respectively) compared to placebo.<\/i>\n<\/li>\n<\/ul>\n<p>\n\u201cWe are thrilled to see this data shared with the scientific community, underscoring this medicine\u2019s potential to address the high unmet need among patients with psoriasis and other immune-mediated diseases,\u201d said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. \u201cThis marks a turning point to the next \u2018chapter\u2019 of Nimbus. We have advanced our leading-edge technologies and grown our expertise in small molecule drug development to deliver breakthrough medicines, by design, for the benefit of patients.\u201d\n<\/p>\n<p>\n<b>About Nimbus Therapeutics<br \/>\n<br \/><\/b>Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus\u2019 pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05128487&amp;esheet=53363887&amp;newsitemid=20230317005414&amp;lan=en-US&amp;anchor=NCT05128487&amp;index=2&amp;md5=bf1eda159f45823fd9e974cb847710f5\" rel=\"nofollow noopener\" shape=\"rect\">NCT05128487<\/a>), as well as a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune conditions and metabolic diseases. Nimbus is headquartered in Boston, MA. To learn more about Nimbus, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nimbustx.com%2F&amp;esheet=53363887&amp;newsitemid=20230317005414&amp;lan=en-US&amp;anchor=www.nimbustx.com&amp;index=3&amp;md5=ca82a424a7d74d02e87494174163b42c\" rel=\"nofollow noopener\" shape=\"rect\">www.nimbustx.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nChris Railey, +1 (617) 834-0936<br \/>\n<br \/>Ten Bridge Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#99;h&#x72;&#105;s&#x40;&#116;e&#x6e;&#98;r&#x69;&#100;g&#x65;&#99;o&#x6d;&#109;u&#x6e;&#105;c&#x61;&#116;i&#x6f;&#110;s&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#104;r&#x69;&#115;&#64;&#x74;&#101;n&#x62;&#114;i&#x64;&#103;e&#x63;&#111;m&#x6d;&#117;n&#x69;&#99;a&#x74;&#105;o&#x6e;&#115;&#46;&#x63;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502\/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. The results were &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54990","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON&#8211;(BUSINESS WIRE)&#8211;Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502\/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. The results were ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-20T13:06:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting\",\"datePublished\":\"2023-03-20T13:06:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/\"},\"wordCount\":445,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005414\\\/en\\\/1741768\\\/21\\\/Nimbus_logo_RGB_NoTM_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/\",\"name\":\"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005414\\\/en\\\/1741768\\\/21\\\/Nimbus_logo_RGB_NoTM_%281%29.jpg\",\"datePublished\":\"2023-03-20T13:06:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005414\\\/en\\\/1741768\\\/21\\\/Nimbus_logo_RGB_NoTM_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005414\\\/en\\\/1741768\\\/21\\\/Nimbus_logo_RGB_NoTM_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend","og_description":"BOSTON&#8211;(BUSINESS WIRE)&#8211;Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502\/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. The results were ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-20T13:06:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting","datePublished":"2023-03-20T13:06:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/"},"wordCount":445,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/","name":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg","datePublished":"2023-03-20T13:06:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230317005414\/en\/1741768\/21\/Nimbus_logo_RGB_NoTM_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/phase-2b-clinical-trial-results-for-tyk2-inhibitor-presented-at-american-academy-of-dermatology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54990"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54990\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}